FK506: Therapeutic Effects on Lupus Dermatoses in Autoimmune-prone MRL/Mp-lpr/lpr Mice

Overview

Journal Arch Dermatol Res

Specialty Dermatology

Date 1995 Jan 1

PMID 7487142

Citations 4

Authors

F Furukawa

S Imamura

M Takigawa

Affiliations

Soon will be listed here.

Abstract

The effects of FK506, a new immunosuppressive agent, on the development of lupus dermatoses were investigated in the autoimmune-prone MRL/Mp-lpr/lpr (MRL/lpr) mouse, which is an animal model for the spontaneous development of skin lesions similar to those of human lupus erythematosus (LE). FK506 reduced the incidence of skin lesions, lupus nephritis, the titre of serum anti-double-stranded DNA antibodies and the massive T cell proliferation. The incidence and magnitude of IgG deposition at the dermoepidermal junction were not changed. These results suggest that FK506 is a promising immunosuppressive agent for the control of autoimmune skin diseases.

Citing Articles

Nephroprotective Potential of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Murine Model of Chronic Cyclosporine Nephrotoxicity.

Ramirez-Bajo M, Martin-Ramirez J, Bruno S, Pasquino C, Banon-Maneus E, Rovira J Front Cell Dev Biol. 2020; 8:296.

PMID: 32432111 PMC: 7214690. DOI: 10.3389/fcell.2020.00296.

Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Zaalberg A, Moradi Tuchayi S, Ameri A, Ngo K, Cunningham T, Eliane J J Invest Dermatol. 2018; 139(1):62-70.

PMID: 30030152 PMC: 6309656. DOI: 10.1016/j.jid.2018.06.185.

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Monneaux F, Muller S Arthritis Res Ther. 2009; 11(3):234.

PMID: 19591653 PMC: 2714128. DOI: 10.1186/ar2711.

Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.

Tzellos T, Kouvelas D Eur J Clin Pharmacol. 2007; 64(4):337-41.

PMID: 18157526 DOI: 10.1007/s00228-007-0421-2.

References

Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, OKUHARA M . FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-55. DOI: 10.7164/antibiotics.40.1249. View

Thomson A, Starzl T . FK 506 and autoimmune disease: perspective and prospects. Autoimmunity. 1992; 12(4):303-13. PMC: 2967358. DOI: 10.3109/08916939209148473. View

Berden J, Faaber P, Assmann K, Rijke T . Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice. Scand J Immunol. 1986; 24(4):405-11. DOI: 10.1111/j.1365-3083.1986.tb02128.x. View

Mountz J, Smith H, Wilder R, Reeves J, Steinberg A . CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol. 1987; 138(1):157-63. View

Takagishi K, Yamamoto M, Nishimura A, Yamasaki G, Kanazawa N, Hotokebuchi T . Effects of FK-506 on collagen arthritis in mice. Transplant Proc. 1989; 21(1 Pt 1):1053-5. View

Horiguchi Y, Furukawa F, Imamura S . Ultrastructural observations of skin lesions in MRL mice--dermal infiltrations and capillary changes. J Dermatol. 1986; 13(6):440-7. DOI: 10.1111/j.1346-8138.1986.tb02972.x. View

Knight J, Adams D, PURVES H . The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid. Clin Exp Immunol. 1977; 28(2):352-8. PMC: 1540763. View

Ohshio G, Furukawa F, Yoshioka H, Taki Y, Manabe T, Ozawa K . High levels of anti-mitochondrial antibodies in MRL mice. Influence of anti-DNA antibodies on anti-mitochondrial antibodies measured by an enzyme-linked immunosorbent assay. Microbiol Immunol. 1987; 31(1):75-81. DOI: 10.1111/j.1348-0421.1987.tb03069.x. View

Takabayashi K, Koike T, Kurasawa K, Matsumura R, Sato T, Tomioka H . Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol. 1989; 51(1):110-7. DOI: 10.1016/0090-1229(89)90211-0. View

10.

Horiguchi Y, Furukawa F, Hamashima Y, Imamura S . Ultrastructural observations of skin lesions in MRL mice--dermoepidermal junction. Arch Dermatol Res. 1984; 276(4):229-34. DOI: 10.1007/BF00414233. View

11.

Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y . Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res. 1984; 276(3):186-94. DOI: 10.1007/BF00414018. View

12.

Meingassner J, Stutz A . Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?. J Invest Dermatol. 1992; 98(6):851-5. DOI: 10.1111/1523-1747.ep12456939. View

13.

Furukawa F, Taniguchi S, Tachibana T, Horiguchi Y, Kanauchi H, Ohshio G . Pathogenesis of lupus dermatoses in autoimmune mice. X. Evaluation of histamine-N-methyltransferase activity in the skin of autoimmune. Microbiol Immunol. 1988; 32(1):83-96. DOI: 10.1111/j.1348-0421.1988.tb01368.x. View

14.

Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T . Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. Immunology. 1990; 69(2):222-7. PMC: 1385593. View

15.

White D . FK506: the promise and the paradox. Clin Exp Immunol. 1991; 83(1):1-3. PMC: 1535465. DOI: 10.1111/j.1365-2249.1991.tb05578.x. View

16.

Kanauchi H, Imamura S, Takigawa M, Furukawa F . Evaluation of the Japanese-Chinese herbal medicine, kampo, for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. J Dermatol. 1994; 21(12):935-9. DOI: 10.1111/j.1346-8138.1994.tb03315.x. View

17.

Tachibana T, Furukawa F, Taniguchi S, Hamashima Y, Imamura S . Histamine metabolism in skin of MRL/l mice. Arch Dermatol Res. 1985; 278(1):57-60. DOI: 10.1007/BF00412497. View

18.

Starzl T, Todo S, Fung J, Demetris A, Venkataramman R, Jain A . FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989; 2(8670):1000-4. PMC: 2966318. DOI: 10.1016/s0140-6736(89)91014-3. View

19.

Kanauchi H, Furukawa F, Imamura S . Characterization of cutaneous infiltrates in MRL/lpr mice monitored from onset to the full development of lupus erythematosus-like skin lesions. J Invest Dermatol. 1991; 96(4):478-83. DOI: 10.1111/1523-1747.ep12470176. View

20.

Brannan C, Itoh N, Yonehara S, Copeland N, Jenkins N, Nagata S . The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992; 148(4):1274-9. View